Literature DB >> 10499619

Patterns of p53 gene mutations in head and neck cancer: full-length gene sequencing and results of primary radiotherapy.

M E Saunders1, R MacKenzie, R Shipman, E Fransen, R Gilbert, R C Jordan.   

Abstract

p53 gene alterations are common in head and neck cancers, but their prognostic value has not been clearly established. Despite evidence in other cancers that sequencing of the entire p53 coding region provides prognostic information, full-length p53 gene sequencing has rarely been performed in head and neck cancers. In this study, p53 was assessed in a series of 42 pretreatment biopsies from patients with laryngeal carcinomas by full-length gene sequencing and by immunohistochemistry (IHC). Associations among p53 genotype, protein expression, and local recurrence were assessed in 35 irradiated patients followed for a minimum of 5 years. DNA was extracted from formalin-fixed, paraffin-embedded biopsies, and exons 2-11 of the p53 gene were individually amplified by PCR and then directly sequenced. IHC was performed to detect mutant and wild-type p53 protein using the DO7 monoclonal antibody. p21 protein expression was assessed using the EA1 monoclonal antibody. Twenty genetic alterations were observed in 42 tumors (48%). Four of these alterations (20%) occurred outside exons 5-8. There was a significant association between p53 gene and protein status (chi2 = 4.18, P = 0.04), although the correlation was weak (phi coefficient = -0.327). Although local relapse following radiation was significantly associated with nodal status, no correlations were observed between p53 status (gene or IHC) and local recurrence following radiation therapy, based on the Kaplan-Meier method. These results show that p53 mutations are common in laryngeal carcinomas and that a proportion occur outside traditionally examined regions. The lack of correlation between p53 status and local control suggests that this marker is not as powerful as traditional prognostic factors, such as lymph node status.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499619

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

Review 1.  Molecular pathogenesis of head and neck squamous cell carcinoma.

Authors:  David Hardisson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-05-08       Impact factor: 2.503

2.  Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.

Authors:  A K Arya; A El-Fert; T Devling; R M Eccles; M A Aslam; C P Rubbi; N Vlatković; J Fenwick; B H Lloyd; D R Sibson; T M Jones; M T Boyd
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

3.  Prognostic factors in tongue cancer - relative importance of demographic, clinical and histopathological factors.

Authors:  S Kantola; M Parikka; K Jokinen; K Hyrynkangs; Y Soini; O P Alho; T Salo
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

4.  Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.

Authors:  Lorea Manterola; Pablo Aguirre; Erika Larrea; María Arestín; Ayman Gaafar; Kepa Elorriaga; Ibai Goicoechea; María Armesto; Marta Fernández-Mercado; Ignacio Zabalza; Juan Carlos López-Duque; Ekhiñe Larruskain; Jon Alexander Sistiaga; Mikel Landa; Aitor Zabala; Francisco Santaolalla; José Antonio Municio; Ángel Ispizua; Juana María García-Pedrero; Juan Pablo Rodrigo; Charles Henderson Lawrie
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

5.  p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma.

Authors:  Wachiraphan Supsavhad; Wessel P Dirksen; Blake E Hildreth; Thomas J Rosol
Journal:  Vet Sci       Date:  2016-08-18

6.  Biological tumor markers associated with local control after primary radiotherapy in laryngeal cancer: A systematic review.

Authors:  Maartje G Noordhuis; Emiel A Kop; Bert van der Vegt; Johannes A Langendijk; Bernard F A M van der Laan; Ed Schuuring; Geertruida H de Bock
Journal:  Clin Otolaryngol       Date:  2020-04-23       Impact factor: 2.597

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.